Domestic Manufacturing CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines Use of industrial chemicals in medical devices Drug shortages and supply chain resilience
2026 · 2nd Quarter (Apr 1 - June 30)
FRESENIUS KABI USA LLC
Filed by FRESENIUS KABI USA LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 20, 2026
- Income
- Not reported
- Expenses
- $580,000.00
- Registrant
- FRESENIUS KABI USA LLC
- Client
- FRESENIUS KABI USA LLC
- Filing UUID
- 7a6fe69d-1bf2-414d-90df-1c5f4757fded
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) PTAB Proposed Rule - Discretionary Denials and One and Done Ancillary Product Patent Reform
Literal federal measure citations: S. 2658
Tax incentives for Onshoring Domestic Manufacturing of Essential Medicines
S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act Section 301 Investigation re: Germany Issues Section 232 of the Trade Expansion Act: Patents as a Barrier to US Manufacturing of Biosimilars Inflation Reduction Act (IRA) redesigned Medicare Part D: Manufacturer Discount Program and Biosimilars CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines PTAB Proposed Rule - Discretionary Denials and One and Done Federal Procurement Preferences for Domestic Medicines Drug Shortages and Supply Chain Resilience
Literal federal measure citations: S. 1954, H.R. 5526, S. 1414
S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines Drug Shortages and Supply Chain Resilience PBM Transparency: Implementation of Consolidated Appropriations Act (CAA) Inflation Reduction Act (IRA) redesigned Medicare Part D: Manufacturer Discount Program and Biosimilars Net Elective Cost Policy: PBM Reform Through Bid Transparency
Literal federal measure citations: S. 2658
S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act PTAB Proposed Rule - Discretionary Denials and One and Done Domestic Production of Essential Medicines Federal Procurement Preferences for Domestic Medicines Ancillary Product Patent Reform CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines Use of Industrial Chemicals in Medical Devices Drug Shortages and Supply Chain Resilience Employee Benefits Security Administration (EBSA) Proposed Rule Re: Broker/Consultant Transparency to Employer Plans Section 301 Investigation re: Germany Issues PBM Transparency: Implementation of Consolidated Appropriations Act (CAA) Section 232 of the Trade Expansion Act: Patents as a Barrier to US Manufacturing of Biosimilars Inflation Reduction Act (IRA) redesigned Medicare Part D: Manufacturer Discount Program and Biosimilars Net Elective Cost Policy: PBM Reform Through Bid Transparency
Literal federal measure citations: S. 2276, H.R. 3269, S. 2658, S. 1954, H.R. 5526, S. 1414
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.